New molecule entities and small molecules

Citoxlab – Helping you put the right drug candidate forward

Citoxlab has more than 40 years’ experience in the development of small molecules, and our senior scientists have contributed to the discovery and development of many of today’s marketed drugs. Our experts can advise on what is needed throughout the development process, from early in silico analysis of liabilities and the first genetic toxicology assays, through to full regulatory packages including carcinogenicity studies.

We have an expert ready to provide customized advice on each phase of your development program for small molecules.

Our expertise in small molecule development includes :

Full range of toxicology studies

  • Discovery
  • Candidate selection
  • First-in-man – IND
  • Full development from IND to NDA
  • Pilot/lead optimization
  • Acute studies
  • Subchronic studies
  • Chronic toxicity
  • Reproductive toxicology
  • Carcinogenicity studies

Diverse animal models

  • Rodents (rats, mice, hamsters)
  • Dogs
  • Non-human primates (cynomolgus and rhesus)
  • Minipigs
  • Rabbits

Diverse routes of administration

  • Gavage, Dietary, Capsule/tablet

Advanced electronic data support

  • Integrated, companywide Provantis™ system for efficient, accurate data capture, entry and reporting
  • In-life
  • Clinical pathology
  • Necropsy
  • Histopathology

Experience with a wide variety of compounds

  • Recombinant proteins, antibodies, peptides, other biopharmaceuticals
  • Vaccines
  • Food additives
  • Veterinary products
  • Synthetic organic chemicals
  • Pesticides
  • Petrochemicals
  • Gene therapy vectors


Find out more by following these links

> Discovery and drug candidate selection

> First-in-man / IND

> From IND to NDA